NG9 Stock Chart & Stats
€12.36
€0.29(2.36%)
At close: 4:00 PM EDT
€12.36
€0.29(2.36%)
Day’s Range― - ―
52-Week Range€4.20 - €13.14
Previous CloseN/A
Volume0.00
Average Volume (3M)9.00
Market Cap
€1.52B
Enterprise Value€1.22K
Total Cash (Recent Filing)€145.54M
Total Debt (Recent Filing)€448.37M
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Nov 10, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.98
Shares Outstanding130,211,780
10 Day Avg. Volume0
30 Day Avg. Volume9
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)0.36
Price to Sales (P/S)0.41
P/FCF Ratio-13.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€15.54Price Target Upside25.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)0.16
Revenue Forecast (FY)€702.69M
Bulls Say, Bears Say
Bulls Say
Revenue Scale And GrowthSustained top-line expansion broadens operational scale and payor negotiating leverage, enabling fixed-cost absorption and investment in labs/sales. Durable revenue momentum supports long-term product rollouts and gives management runway to drive margin recovery and commercial investments.
NGS Mix ShiftA faster-growing NGS mix increases average unit revenue and clinical differentiation, making offerings stickier with oncologists and pharma. Structural shift to higher-complexity testing supports sustainable margin expansion and positions NeoGenomics to capture growth from precision oncology and trial biomarker demand.
Improving Cash Flow And EBITDAPositive operating cash flow and rising adjusted EBITDA signal improving cash conversion and operational leverage. This durable improvement reduces reliance on external financing, supports planned investment in commercial reps and R&D, and increases probability of sustainable free cash flow.
Bears Say
Continued Negative MarginsPersistent operating and net losses constrain internal capital generation and limit return on equity. Until margins turn positive, the firm will remain dependent on external funding for strategic initiatives, and sustained negative returns could pressure long-term financial flexibility and investor support.
Refinancing And Capital Structure RiskMaterial convertible maturities require successful refinancing or capital raises. Execution risk in capital markets can lead to dilution, higher financing costs, or constrained strategic actions. This structural liability affects long-term balance sheet flexibility and could alter investor returns if markets are unfavorable.
Reimbursement Uncertainty For New TestsDelayed commercial payer coverage slows monetization of strategic launches, compresses early margins, and prolongs payback on commercial investments. Structural uncertainty in reimbursement policy can limit adoption rates and revenue realization for novel diagnostics over multiple quarters.
NeoGenomics News
NG9 FAQ
What was NeoGenomics’s price range in the past 12 months?
NeoGenomics lowest stock price was €4.20 and its highest was €13.13 in the past 12 months.
What is NeoGenomics’s market cap?
NeoGenomics’s market cap is €1.52B.
When is NeoGenomics’s upcoming earnings report date?
NeoGenomics’s upcoming earnings report date is Nov 10, 2026 which is in 103 days.
How were NeoGenomics’s earnings last quarter?
NeoGenomics released its earnings results on Jul 28, 2026. The company reported €0.044 earnings per share for the quarter, beating the consensus estimate of €0.03 by €0.014.
Is NeoGenomics overvalued?
According to Wall Street analysts NeoGenomics’s price is currently Undervalued.
Does NeoGenomics pay dividends?
NeoGenomics does not currently pay dividends.
What is NeoGenomics’s EPS estimate?
NeoGenomics’s EPS estimate is 0.05.
How many shares outstanding does NeoGenomics have?
NeoGenomics has 130,211,780 shares outstanding.
What happened to NeoGenomics’s price movement after its last earnings report?
NeoGenomics reported an EPS of €0.044 in its last earnings report, beating expectations of €0.03. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of NeoGenomics?
Currently, no hedge funds are holding shares in DE:NG9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NeoGenomics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€15.54 (25.73% Upside)
€15.54 (25.73% Upside)
Blogger Sentiment
Bullish
DE:NG9 Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $118.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
116.35%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-15.92%
Trailing 12-Months
Company Description
NeoGenomics
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics' advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Additionally, the company provides immunohistochemistry and digital imaging services, enabling the localization of cellular proteins in tissue sections, visualization of scanned slides, and quantitative analysis. Molecular testing, focusing on DNA/RNA analysis and gene structure/function, is also a key offering, alongside morphologic analysis where pathologists microscopically diagnose cells. Beyond clinical diagnostics, NeoGenomics supports pharmaceutical clients' oncology programs from discovery to commercialization and acts as a reference laboratory for anatomic pathology testing. The company, founded in 2001 and headquartered in Fort Myers, Florida, also maintains a strategic alliance and laboratory services agreement with Inivata Limited.
NG9 Company Deck
NG9 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive operational and financial trajectory: consistent double-digit top-line growth, strong NGS performance (+26% YoY) with favorable mix shift (NGS now ~1/3 of clinical revenue), adjusted EBITDA expansion (+27% YoY), early commercial and reimbursement wins (PanTracer MolDX approval, RaDaR ST launch), and an increase to full-year revenue guidance. Offsetting risks include a meaningful nonclinical decline (-15% YoY), first-quarter gross margin headwinds (–80 bps) from acquisition and pre-approval launch timing, freight/fuel cost pressure, payer coverage timing for new products, and the need to refinance a sizable convertible in 2028. On balance, the positive growth, margin recovery plans, product launches, and improved cash flow prospects outweigh the near-term headwinds.View all DE:NG9 earnings summariesNG9 Stock 12 Month Forecast
Average Price Target
€15.54
▲(25.73% Upside)